Noorik is looking for potential partners.

The key features of our asset are:

• 
  Reprofiling of an established drug in new indication
• 
  The key features of our asset are:
• 
  Reprofiling of an established drug in new indication
• 
  Short development plan, low investment and lower risk than traditional R&D projects
• 
  One focus: Acute Kidney Injury
• 
  One asset: N-003
• 
  Clinical stage to enter Phase II in 2016
• 
  Potential to be first therapy for Acute Kidney Injury

If you would like to know more, please contact us.